PF 07915234
Alternative Names: BNT 167; PF-07915234; Varicella Zoster Virus modified RNA vaccine - Pfizer; Varicella Zoster Virus modRNA vaccine - Pfizer; VZV modRNA vaccine - PfizerLatest Information Update: 08 Mar 2023
At a glance
- Originator BioNTech; Pfizer
- Developer Pfizer
- Class RNA vaccines; Varicella vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Herpes zoster
Most Recent Events
- 30 Jan 2023 Preclinical trials in Herpes zoster in USA (IM) before January 2023
- 30 Jan 2023 Pfizer plans a phase I/II trial for Herpes zoster (Prevention, In adults, In the elderly) in USA in January 2023 (NCT05703607)
- 25 Jan 2023 Phase-I/II clinical trials in Herpes zoster (Prevention, In adults, In the elderly) in USA (IM) (NCT05703607)